Epidiolex liver check: is Long-Term use safe?
NCT ID NCT05044819
First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study follows 154 people taking Epidiolex (cannabidiol) for seizures caused by Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Researchers will monitor for signs of chronic liver injury and fibrosis over time using blood tests and liver scans. The goal is to understand the long-term liver safety of this medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cannabidiol (Epidiolex) oral solution
What this could lead to
If successful, this study could confirm that long-term use of Epidiolex is safe for the liver, reassuring patients and doctors.
What could go wrong
This is an observational safety study, not a test of effectiveness. It may find liver risks that limit use, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LENNOX GASTAUT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Little Rock, Arkansas, 72758, United States
-
Clinical Trial Site
Downey, California, 90242, United States
-
Clinical Trial Site
Long Beach, California, 90806, United States
-
Clinical Trial Site
Sacramento, California, 95817, United States
-
Clinical Trial Site
Miami, Florida, 33136, United States
-
Clinical Trial Site
Miami, Florida, 33176, United States
-
Clinical Trial Site
Orlando, Florida, 32806, United States
-
Clinical Trial Site
Tampa, Florida, 33606, United States
-
Clinical Trial Site
Augusta, Georgia, 30912, United States
-
Clinical Trial Site
Wichita, Kansas, 67214, United States
-
Clinical Trial Site
Lexington, Kentucky, 40504, United States
-
Clinical Trial Site
Baltimore, Maryland, 21205, United States
-
Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
Clinical Trial Site
New Brunswick, New Jersey, 08901, United States
-
Clinical Trial Site
New York, New York, 10016, United States
-
Clinical Trial Site
Charlotte, North Carolina, 28203, United States
-
Clinical Trial Site
Durham, North Carolina, 27708, United States
-
Clinical Trial Site
Cincinnati, Ohio, 45219, United States
-
Clinical Trial Site
Oklahoma City, Oklahoma, 73104, United States
-
Clinical Trial Site
Philadelphia, Pennsylvania, 19107, United States
-
Clinical Trial Site
Charleston, South Carolina, 29425, United States
-
Clinical Trial Site
Austin, Texas, 78758, United States
-
Clinical Trial Site
Dallas, Texas, 75251, United States
-
Clinical Trial Site
Houston, Texas, 77030, United States
-
Clinical Trial Site
Round Rock, Texas, 78681, United States
-
Clinical Trial Site
Winchester, Virginia, 22601, United States